Literature DB >> 22497867

Hematopoietic growth factors: personalization of risks and benefits.

Shannon Puhalla1, Saveri Bhattacharya, Nancy E Davidson.   

Abstract

A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22497867      PMCID： PMC5528376          DOI： 10.1016/j.molonc.2012.03.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  32 in total

1.  Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma.

Authors:  Nicole J Watring; Thomas W Wagner; James J Stark
Journal:  Am J Emerg Med       Date:  2007-02       Impact factor: 2.469

2.  Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Authors:  William G Martin; Kay M Ristow; Thomas M Habermann; Joseph P Colgan; Thomas E Witzig; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

Review 3.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  J Bohlius; J Wilson; J Seidenfeld; M Piper; G Schwarzer; J Sandercock; S Trelle; O Weingart; S Bayliss; S Brunskill; B Djulbegovic; C L Benett; S Langensiepen; C Hyde; E Engert
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

4.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

5.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

Review 6.  Hematopoietic growth factors: personalization of risks and benefits.

Authors:  Shannon Puhalla; Saveri Bhattacharya; Nancy E Davidson
Journal:  Mol Oncol       Date:  2012-03-20       Impact factor: 6.603

7.  Functional erythropoietin autocrine loop in melanoma.

Authors:  Suresh M Kumar; Geza Acs; Dong Fang; Meenhard Herlyn; David E Elder; Xiaowei Xu
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.

Authors:  R Pettengell; H Gurney; J A Radford; D P Deakin; R James; P M Wilkinson; K Kane; J Bentley; D Crowther
Journal:  Blood       Date:  1992-09-15       Impact factor: 22.113

Review 9.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

10.  Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature.

Authors:  Nehal Masood; Asim Jamal Shaikh; Wasim Ahmed Memon; Romana Idress
Journal:  Cases J       Date:  2008-12-24
View more
  5 in total

Review 1.  Hematopoietic growth factors: personalization of risks and benefits.

Authors:  Shannon Puhalla; Saveri Bhattacharya; Nancy E Davidson
Journal:  Mol Oncol       Date:  2012-03-20       Impact factor: 6.603

2.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Authors:  Ingunn M Stromnes; J Scott Brockenbrough; Kamel Izeradjene; Markus A Carlson; Carlos Cuevas; Randi M Simmons; Philip D Greenberg; Sunil R Hingorani
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059

3.  Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.

Authors:  Renata Ferrarotto; Ian Anderson; Balazs Medgyasszay; Maria Rosario García-Campelo; William Edenfield; Trevor M Feinstein; Jennifer M Johnson; Sujith Kalmadi; Philip E Lammers; Alfredo Sanchez-Hernandez; Yili Pritchett; Shannon R Morris; Rajesh K Malik; Tibor Csőszi
Journal:  Cancer Med       Date:  2021-08-18       Impact factor: 4.452

4.  Physical performance limitations in adolescent and adult survivors of childhood cancer and their siblings.

Authors:  Corina S Rueegg; Gisela Michel; Laura Wengenroth; Nicolas X von der Weid; Eva Bergstraesser; Claudia E Kuehni
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

5.  Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression.

Authors:  Akash Saggam; Prathamesh Kale; Sushant Shengule; Dada Patil; Manish Gautam; Girish Tillu; Kalpana Joshi; Sunil Gairola; Bhushan Patwardhan
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.